BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//www.barthsyndrome.org//NONSGML kigkonsult.se iCalcreator 2.30.10/
 /
CALSCALE:GREGORIAN
METHOD:PUBLISH
UID:a3da47f9-9172-4a1f-b99b-0c1fb54deb31
X-WR-CALDESC:Topics include the expanding role of biomarkers and updates on
  potassium binding agents\, SGLT2 inhibitors and ARNIs. There will be talk
 s on\nremote monitoring\, pulmonary arterial hypertension (PAH)\, new evid
 ence of the beneficial effects of percutaneous treatment of valvular heart
  disease and the marked improvements in outcome that are now being seen wi
 th LVADs and cardiac transplantation. We’ll discuss old and new indication
 s for DOAC’s\, take an extensive look at the treatment of ventricular arrh
 ythmias and review the role of left atrial closure devices and percutaneou
 s cardiac pumps. The last session includes talks on some of the more probl
 ematic areas of patient management including\, mid range EF\, adults with 
 congenital lesions and finally an overview of new and emerging therapies. 
 As you can see\, the 20th
X-WR-RELCALID:c5e0f650003a1613a1704cbf3803ccf8
X-WR-TIMEZONE:America/New_York
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:STANDARD
TZNAME:EST
DTSTART:20191103T020000
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
RDATE:20201101T020000
END:STANDARD
BEGIN:DAYLIGHT
TZNAME:EDT
DTSTART:20190310T020000
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
RDATE:20200308T020000
RDATE:20210314T020000
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
UID:8d474df8-f658-4a2f-b092-6b184a112899
DTSTAMP:20260429T011522Z
DESCRIPTION:Topics include the expanding role of biomarkers and updates on 
 potassium binding agents\, SGLT2 inhibitors and ARNIs. There will be talks
  on\nremote monitoring\, pulmonary arterial hypertension (PAH)\, new evide
 nce of the beneficial effects of percutaneous treatment of valvular heart 
 disease and the marked improvements in outcome that are now being seen wit
 h LVADs and cardiac transplantation. We’ll discuss old and new indications
  for DOAC’s\, take an extensive look at the treatment of ventricular arrhy
 thmias and review the role of left atrial closure devices and percutaneous
  cardiac pumps. The last session includes talks on some of the more proble
 matic areas of patient management including\, mid range EF\, adults with c
 ongenital lesions and finally an overview of new and emerging therapies. A
 s you can see\, the 20th
DTSTART;TZID=America/New_York:20200110T000000
DTEND;TZID=America/New_York:20200112T235900
LOCATION:La Jolla\, California
SUMMARY:20th Annual San Diego Heart Failure Symposium for Primary Care and 
 Internal Medicine Physicians (endorsed by Heart Failure Society of America
 )
END:VEVENT
END:VCALENDAR